Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
Rhea-AI Summary
Silo Pharma (Nasdaq: SILO) has secured a new U.S. patent (projected number 12,239,614) for its lead asset SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent, titled 'Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females,' will be issued on March 4, 2025.
This patent builds upon previously issued U.S. Patent 11,491,120 from November 2022, adding new claims and strengthening the company's intellectual property portfolio. The development supports Silo's collaborative research with Columbia University and advances their efforts toward clinical trials for SPC-15.
Positive
- New U.S. patent granted strengthening IP protection for lead asset SPC-15
- Patent builds upon existing IP portfolio from November 2022
- Strategic collaboration with Columbia University reinforced
Negative
- Product still in developmental stage, not yet in clinical trials
Insights
Silo Pharma's new patent issuance represents a strategic expansion of their intellectual property portfolio in the competitive PTSD treatment landscape. The patent specifically targets stress-induced affective disorders in females, highlighting a gender-differentiated approach that addresses the well-documented higher prevalence and different manifestation of PTSD in women compared to men.
The intranasal delivery mechanism protected by this patent offers potential advantages over traditional oral medications, including faster onset of action and improved bioavailability by bypassing first-pass metabolism. For PTSD patients experiencing acute symptoms, this delivery route could provide critical therapeutic benefits.
From an investment perspective, this patent strengthens Silo's competitive moat in three key ways:
- Extends protection timeline for their lead asset SPC-15
- Broadens claims coverage beyond their original 2022 patent
- Reinforces their Columbia University collaboration, providing access to institutional research capabilities despite Silo's resources (
$5.85M market cap)
For a developmental-stage company like Silo, robust patent protection is essential for attracting potential licensing partners or acquisition interest. The patent issuance likely positions SPC-15 closer to clinical trials, though significant funding hurdles remain before commercialization.
Investors should monitor upcoming announcements regarding preclinical data, IND filing plans, and potential partnership discussions as indicators of SPC-15's progression toward clinical development.
SARASOTA, FL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) issued an Issue Notification for our previously filed patent application (No. 17/954,864) titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” The projected patent number is 12,239,614 and the issue date of such patent will be March 4, 2025.
The patent reinforces protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent includes newly added claims to U.S. Patent 11,491,120, which was issued to Silo in November 2022.
“Strategic IP and patent expansion is key to advancing our lead asset SPC-15 to clinical trials and creating value for our full pipeline of novel assets,” said Eric Weisblum, CEO of Silo. “This new patent further supports our collaborative research with Columbia University and expands coverage for SPC-15.”
Silo announced the USPTO’s Notice of Allowance for the new patent in January 2025.
About SPC-15
SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA’s streamlined 505(b)(2) regulatory pathway, SPC-15 offers a promising approach to accelerate the approval process. Silo Pharma is collaborating with Columbia University to conduct preclinical studies and has exclusive global rights to the development and commercialization of SPC-15.
About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
FAQ
What is the new patent granted to Silo Pharma (SILO) for PTSD treatment?
When will Silo Pharma's new PTSD treatment patent be issued?
How does the new patent strengthen SILO's intellectual property portfolio?
What is the significance of Silo Pharma's collaboration with Columbia University?
